Big Pharma-backed AdvanCell, flush with $315M series D, ready to put radiotherapy pedal to the metal

Less than a month after locking down a lease for a new U.S. headquarters, radiotherapy outfit AdvanCell is poised to push its lead prostate cancer candidate into phase 3 development with the help of a $315 million series D.